Released May 13, 2026, before the open
10-Q filed May 13, 2026, 43 days after period end · 0001193125-26-220696
Q1 2026 · 10-Q
Revenue$1.30M$1.30M −20.3% vs Q1 2025−5.1% vs Q4 2025
Net Income-$31.21M-$31.21M N/M vs Q1 2025N/M vs Q4 2025
EPS Diluted-$0.26-$0.26 N/M vs Q1 2025no prior Q4 2025 on file
Operating Income-$33,000,000N/M
Operating Cash Flow-$30,822,000N/M
Free Cash Flowderived-$31,061,000N/M
Margins · derived
Operating margin-2540.4%−6.3 pt vs Q1 2025
Net margin-2402.8%−93.4 pt vs Q1 2025
What the release said
The release
Same quarter
| Metric | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 |
|---|---|---|---|---|
| Revenue | $1.30M | $1.63M | $1.93M | $58.98M |
| Net Income | -$31.21M | -$37.62M | -$48.00M | -$18.88M |
| EPS Diluted | -$0.26 | -$0.32 | -$0.47 | -$0.19 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR